Luo Li, Gansevoort Ron T, Kieneker Lyanne M, de Boer Rudolf A, Chen Zekai, Aboumsallem Joseph Pierre, Snieder Harold, Thio Chris H L
Department of Nephrology, University Medical Center Groningen, University of Groningen, The Netherlands.
Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, Rotterdam, The Netherlands.
Kidney Med. 2025 Jul 7;7(9):101065. doi: 10.1016/j.xkme.2025.101065. eCollection 2025 Sep.
RATIONALE & OBJECTIVE: Chronic kidney disease (CKD) is reported to be associated with cancer, especially for urinary tract and lung cancer. However, whether this suggests causality has not been resolved. This study aimed to investigate the causal relation of CKD to overall, urinary tract, and lung cancer.
Mendelian randomization (MR) analysis.
SETTING & PARTICIPANTS: Single-nucleotide polymorphism (SNP)-CKD data were obtained from genome-wide association studies of a meta-analysis of CKDGen and UK Biobank. SNP-cancer data from genome-wide association studies of several community-based and cancer-specific consortia were extracted and then meta-analyzed.
Impaired kidney function (creatinine-based estimated glomerular filtration rate [eGFRcr] <60 mL/min/1.73 m), increased albuminuria (urinary albumin-creatinine ratio [UACR] >30 mg/g), and on a continuous scale, eGFRcr, cystatin C-based eGFR (eGFRcys), and UACR.
Incidences of overall cancer, urinary tract cancer, and lung cancer.
Pooled MR estimates of single-SNP Wald ratios were obtained using an inverse variance-weighted method.
In inverse variance-weighted MR analyses, a higher genetic liability to impaired kidney function was not significantly associated with higher overall cancer risk (OR, 1.00; 95% CI, 1.00-1.01; = 0.06). No associations of other kidney phenotypes including increased albuminuria, eGFRcr, eGFRcys, and UACR with overall cancer risk were found at the Bonferroni-corrected significance level (all > 0.0025). Similarly, risk estimates of generally null were detected in the associations of all these CKD phenotypes with specifically urinary tract and lung cancer (all > 0.0025). The results of our sensitivity analyses, including pleiotropy-robust MR, reverse MR, and multivariable MR analyses, corroborated the results of our main analyses.
Uncertain extrapolation to other ethnicities.
Genetically predicted CKD is not associated with the risk of incident overall, urinary tract, and lung cancer. Our findings thus provide no genetic evidence for a causal relationship between CKD and cancer.
据报道,慢性肾脏病(CKD)与癌症相关,尤其是泌尿系统和肺癌。然而,这是否意味着因果关系尚未明确。本研究旨在探讨CKD与总体癌症、泌尿系统癌症和肺癌之间的因果关系。
孟德尔随机化(MR)分析。
单核苷酸多态性(SNP)-CKD数据来自CKDGen和英国生物银行荟萃分析的全基因组关联研究。提取了来自几个基于社区和癌症特异性联盟的全基因组关联研究的SNP-癌症数据,然后进行荟萃分析。
肾功能受损(基于肌酐的估计肾小球滤过率[eGFRcr]<60 mL/min/1.73 m²)、蛋白尿增加(尿白蛋白肌酐比值[UACR]>30 mg/g),以及连续变量eGFRcr、基于胱抑素C的eGFR(eGFRcys)和UACR。
总体癌症、泌尿系统癌症和肺癌的发病率。
采用逆方差加权法获得单SNP Wald比值的汇总MR估计值。
在逆方差加权MR分析中,肾功能受损的较高遗传易感性与总体癌症风险升高无显著相关性(OR,1.00;95%CI,1.00-1.01;P = 0.06)。在Bonferroni校正的显著性水平下,未发现其他肾脏表型(包括蛋白尿增加、eGFRcr、eGFRcys和UACR)与总体癌症风险之间存在关联(所有P>0.0025)。同样,在所有这些CKD表型与特定泌尿系统和肺癌的关联中,风险估计值通常为零(所有P>0.0025)。我们的敏感性分析结果,包括多效性稳健MR、反向MR和多变量MR分析,证实了我们主要分析的结果。
难以外推至其他种族。
基因预测的CKD与总体、泌尿系统和肺癌的发病风险无关。因此,我们的研究结果没有为CKD与癌症之间的因果关系提供基因证据。